Convergent Therapeutics, Inc.

About

Convergent Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company focuses on developing next-generation targeted radiotherapies, particularly alpha radioantibodies, aimed at treating prostate cancer and other cancers. Their proprietary dual-targeted radionuclide therapies utilize monoclonal antibodies conjugated with alpha-emitting isotopes, such as actinium-225, to effectively target cancer cells while minimizing harm to healthy tissues. The lead product candidate, CONV01-α, targets prostate-specific membrane antigen (PSMA) and is designed for PSMA-positive castration-resistant prostate cancer. It has shown promising results in Phase 1/2 trials and has received FDA clearance for its IND application, with Phase 2 trials set to begin in 2024. Another candidate, In-111 rosopatamab tetraxetan, is also in Phase 2 development for the same indication. Convergent Therapeutics employs innovative radioantibody technology to enhance the precision of radiation therapy, focusing on improving treatment outcomes for cancer patients.